Provided by Tiger Fintech (Singapore) Pte. Ltd.

Y-mAbs Therapeutics, Inc.

4.08
-0.0500-1.21%
Volume:68.01K
Turnover:276.10K
Market Cap:184.49M
PE:-6.09
High:4.12
Open:4.09
Low:3.94
Close:4.13
Loading ...

Y-mAbs Therapeutics - Expects Restructuring Expenses of up to $2.6 Mln

THOMSON REUTERS
·
10 Jan

BRIEF-Y-Mabs Appoints Doug Gentilcore As Head Of Danyelza Unit

Reuters
·
10 Jan

Y-mAbs Appoints Experienced Commercial Leader as Head of Danyelza Business Unit

THOMSON REUTERS
·
10 Jan

Press Release: Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

Dow Jones
·
10 Jan

Y-mAbs Provides Strategic Business Update and 2025 Priorities

THOMSON REUTERS
·
10 Jan

Y-mAbs Therapeutics Inc - to Dose First Nhl Patient in Study 1201 in Q1 2025

THOMSON REUTERS
·
10 Jan

Y-mAbs Therapeutics: Intends to Move Some Roles From Denmark to U.S.

THOMSON REUTERS
·
10 Jan

Y-mAbs Therapeutics Inc - Anticipates Workforce Reduction of up to 13%

THOMSON REUTERS
·
10 Jan

Y-mAbs Provides Strategic Business Update and 2025 Priorities

GlobeNewswire
·
10 Jan

Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA

TipRanks
·
08 Jan

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
23 Dec 2024

We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely

Simply Wall St.
·
20 Dec 2024

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Simply Wall St.
·
11 Dec 2024

Brookline Capital Initiates Y-mAbs Therapeutics at Buy With $17 Price Target

MT Newswires Live
·
05 Dec 2024

Y-mAbs Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
05 Dec 2024

Oppenheimer Initiates Coverage on Y-mAbs Therapeutics With Outperform Rating, $23 Price Target

MT Newswires Live
·
18 Nov 2024

Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth

Simply Wall St.
·
18 Nov 2024

Y-mAbs Therapeutics Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Nov 2024

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

TIPRANKS
·
11 Nov 2024

Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

GuruFocus.com
·
09 Nov 2024